What's new
This page lists items that we have published for the first time or updated in the last 7, 30 or 60 days. Use the filters to narrow results by audience, product type, content type or topic.
You can also stay informed by:
- subscribing to our updates to receive same-day notification emails on safety information, scheduling updates or media releases.
- checking for open consultations.
- joining any upcoming events.
This page is in Beta testing. We welcome your feedback and suggestions as we look to improve this page.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Topic
- Advertising (3)
- Breast implant hub (1)
- Committees and advisory bodies (3)
- Compliance and enforcement (6)
- Cosmetics (1)
- COVID-19 (1)
- Import and export (2)
- Labelling and packaging (2)
- Legislation (1)
- Manufacturing (4)
- Medicinal cannabis hub (1)
- Safety monitoring and information (15)
- Shortages and supply disruptions (7)
- Sunscreens (4)
- Unique Device Identification (UDI) hub (1)
- Urogynaecological (transvaginal) surgical mesh hub (1)
- Vaping hub (2)
- Weight loss products (2)
What's new
95 result(s) found, displaying 76 to 95
-
PageFind contact details for the state and territory recall coordinators as well as the Australian recall coordinator.
-
PageFind out how we approach and manage compliance with the regulation of vapes in Australia.
-
Corporate reportsFind out about the seasonal influenza vaccines available for the 2026 southern hemisphere season.
-
BlogTaking too much vitamin B6 can result in harmful side effects, including nerve damage known as ‘peripheral neuropathy’, which can be severe and irreversible. If you’re not sure if you’re taking too much vitamin B6 have a chat with your doctor or pharmacist.
-
DatasetSearch companion diagnostics (CDx) we have approved for supply in Australia.
-
Prescription medicine decision summaryElahere (mirvetuximab soravtansine) has been approved to treat adults with folate receptor-alpha (FRα) positive cancer of the ovary, fallopian tubes, or peritoneum who have stopped responding to platinum based chemotherapy and who have had one to 3 chemotherapy treatments before.
-
Australian public assessment report (AusPar)Lynkuet is indicated for the treatment of moderate to severe vasomotor symptoms (VMS) associated with menopause.
-
Australian public assessment report (AusPar)Lytgobi (futibatinib) has been approved for the treatment of locally advanced or metastatic intrahepatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or rearrangement that have progressed after at least one prior line of systemic therapy.
-
PageNew Active Substance (NAS) work sharing initiative through ACCESS consortium.
-
PageCheck your product is a medical device that needs to be included in the Australian Register of Therapeutic Goods (ARTG).
-
News articlesInformation on the recently announced concept papers proposing to update the Good Manufacturing Practice (GMP) guide for Annex 6 and Annex 15.
-
FormsThis form is to be completed by the ingredient owner to authorise sponsors to use a protected ingredient that is the subject of an exclusivity period to list a medicine in the Register
-
PageThe aim is to improve clarity, efficiency and internationally harmonise our regulatory framework, wherever possible.
-
GuidanceGuidance to help sponsors understand the potential overlap between certain foods, medicines, devices and cosmetics.
-
PageBe careful about buying medicines or medical devices online they can be unsafe or counterfeit.
-
DatasetSearch our database of cancellations and suspensions from the ARTG.
-
Safety alertsWe are issuing an updated safety advisory after testing confirmed counterfeit imported weight loss products.
-
Australian public assessment report (AusPar)Hepcludex (bulevirtide) is approved for treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.
-
PageSerious Scarcity Substitution Instruments (SSSIs) allow community pharmacists to substitute specific medicines without prior approval from the prescriber so long as the permitted circumstances within the SSSI are met.
-
Regulatory decision noticesListed medicine ingredients and requirements for their use have been updated in the Therapeutic Goods (Permissible Ingredients) Determination (No. 1) 2026, which commenced on 1 March 2026.